Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

TO THE EDITOR: Myeloid malignancies are clonal proliferative diseases with shared but diverse phenotype characteristics; this classification includes (1) the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF); (2) chronic myeloid

[1]  E. Pitkänen,et al.  Germline alterations in a consecutive series of acute myeloid leukemia , 2018, Leukemia.

[2]  R. Houlston,et al.  Genome-wide association studies of cancer: current insights and future perspectives , 2017, Nature Reviews Cancer.

[3]  A. Shimamura,et al.  Genetic predisposition to hematologic malignancies: management and surveillance. , 2017, Blood.

[4]  O. Aalen,et al.  The surprising implications of familial association in disease risk , 2017, BMC Public Health.

[5]  Nicholas Eriksson,et al.  Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. , 2016, Blood.

[6]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[7]  J. Olsen,et al.  Familial risk of non-Hodgkin lymphoma by sex, relationship, age at diagnosis and histology: a joint study from five Nordic countries , 2016, Leukemia.

[8]  Christopher A. Miller,et al.  Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. , 2015, Blood.

[9]  Paola Guglielmelli,et al.  Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms , 2015, Nature Communications.

[10]  K. Hemminki,et al.  Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry , 2012, International journal of cancer.

[11]  M. Björkholm,et al.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[13]  M. Björkholm,et al.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. , 2008, Blood.

[14]  M. Cazzola,et al.  Disease anticipation in familial myeloproliferative neoplasms. , 2008, Blood.

[15]  M. Cazzola,et al.  Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Hemminki,et al.  No Evidence for Anticipation in Lymphoproliferative Tumors in Population-Based Samples , 2005, Cancer Epidemiology Biomarkers & Prevention.

[17]  K. Hemminki,et al.  Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans , 2004, Journal of Medical Genetics.

[18]  Kari Hemminki, Xinjun Li, Kamila Plna, Charlotta Granst.  The Nation-wide Swedish Family-Cancer Database&Updated Structure and Familial Rates , 2001 .

[19]  K. Hemminki,et al.  Familial polycythemia vera: results from the Swedish Family-Cancer Database , 2001, Leukemia.